Page 2

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Cancel claims 1-64.

65. (New) A method for the treatment of metabolic diseases or dysfunctions, selected from the group consisting of obesity, diabetes, metabolic syndrome, eating disorder, cachexia, hypercholesterolemia, and dyslipidemia, comprising administering a CG7956 nucleic acid molecule, a polypeptide encoded thereby according to SEQ ID NO:14, SEQ ID NO:15 or ENSMUSP00000045910, or a fusion polypeptide comprising said polypeptide, to a patient in need of such treatment in an amount effective to treat said metabolic diseases or dysfunctions, wherein said polypeptide is an insect or a mammalian polypeptide.

- 66. (New) The method of claim 65, wherein the polypeptide is a recombinant polypeptide.
- 67. (New) The method of claim 66, wherein said recombinant polypeptide is a fusion polypeptide.
- 68. (New) The method according to claim 65, wherein said CG7956 nucleic acid molecule, a polypeptide encoded thereby or a fusion polypeptide comprising said polypeptide is combined with a pharmaceutically acceptable carrier, diluent and/or

additive prior to administration to said patient.

69. (New) A composition comprising a recombinant polypeptide encoded by CG7956 nucleic acid molecule together with acceptable carriers, diluents and/or additives,

wherein said polypeptide is a fusion polypeptide.

70. (New) A method for regulating triglyceride metabolism and/or adipogenesis in a patient, comprising administering a CG7956 nucleic acid molecule, a polypeptide encoded thereby according to SEQ ID NO:14, SEQ ID NO:15 or ENSMUSP00000045910, or a fusion polypeptide comprising said polypeptide, to a patient in need of such treatment in an amount effective to regulate triglyceride metabolism and/or adipogenesis, wherein said polypeptide is an insect or a mammalian polypeptide.

71. (New) The method according to claim 70, wherein said patient is suffering from a metabolic disease or dysfunction selected from the group consisting of obesity, diabetes, metabolic syndrome, eating disorder, cachexia, hypercholesterolemia, and dyslipidemia.